Arrhythmogenic right ventricular cardiomyopathy (ARVC) is seen predominantly in males, and 30% to 50% of these cases have family members affected in some way. 1 ARVC is seen in 1/10,000 of the US population but may be more common because it lacks overt symptoms. The first clinical signs are usually during adolescence, and unfortunately, ARVC accounts for up to 17% of all sudden cardiac deaths in this age group. 2, 3 Ninety percent have some electrocardiogram (EKG) abnormality.
Case Presentation
A man in his early 20s presented to the emergency room with shortness of breath. An echocardiogram was ordered to evaluate for evidence of pulmonary embolism. An EKG was completed, and an abnormality was found. The EKG showed ventricular tachycardia and left bundle branch block. The echocardiogram showed normal left ventricular function with a measured ejection fraction (EF) of 55%. The septal flattening suggested right ventricular volume or pressure overload. The right ventricle was severely enlarged, and its global function was severely reduced. The tricuspid valve was moderately regurgitant. The left ventricle did not appear affected (see Figure 1 ).
The patient elected medical management to control the arrhythmia with beta-blockers and to prevent thrombus formation with an anticoagulant therapy. Anticoagulation should be used in ARVC patients with a large, hypokinetic right ventricle (RV) and slow blood flow. No follow-up testing was available.
Discussion
ARVC is due to genetic mutation resulting in a lack of proteins that normally link cells together. The disease is autosomal dominant but without complete expression. For example, a person with the genetic abnormality may not actually develop the disease (incomplete penetrance). 4 Advances have been made in identifying ARVC by detecting the genetic mutations. ARVC results from the loss of the proteins plakoglobin and desmoplakin, which are components of the junctions responsible for linking cells to one another. In cardiac muscle, the lack of the protein results in loss of muscle and RV wall thinning. The chamber dilates, which leads to RV dysfunction. Associated arrhythmias are caused by the interruption of electrical energy through this damaged muscle. Over time, the damaged or dead muscle cells are replaced with scar tissue and fat. Echocardiographically, this appears as a patchy appearance of the RV. The progression may continue into the left ventricle.
Early in the disease process, subtle structural changes in the right ventricle result in minor ventricular arrhythmia-like ventricular tachycardia. Patients usually have no symptoms in this early concealed phase but are at risk of sudden death, especially during high exertion (athletes). Progression into an overt phase continues with noticeable structural changes with palpitations, presyncope/syncope, and ventricular arrhythmia. Next follows RV dysfunction and dilation. Symptoms of peripheral edema and swelling of the abdomen are noticed. Finally, a decrease in left ventricular function occurs as the disease spreads, and breathlessness becomes a common symptom.
A single test is rarely able to diagnose ARVC. EKGs, signal-averaged EKGs, Holter monitors, exercise tests, and echocardiograms are all part of a basic screening process. Cardiac catheterization and electrophysiology studies might be required in some family members. EKGs may show injured muscle with low-amplitude, high-frequency signals (late potentials). Arrhythmia is a prominent presentation of patients with ARVC and includes premature ventricular beats, nonsustained ventricular tachycardia, or sustained ventricular tachycardia. 1, 5 "Epsilon waves" in V1 to V3 and prolongation of QRS (>110 ms) in V1 to V3 are major criteria in diagnosing ARVC. Exercise testing, with strenuous activity, may trigger arrhythmias. 2, 6 Echo is a critical diagnostic tool and may show an enlarged, hypokinetic right ventricle with a paper-thin right ventricle free wall. RV aneurysms may be visualized in the wall. The dilation of the right ventricle will stretch the tricuspid annulus, leading to regurgitation. Paradoxical septal motion may also be evident. Some dyssynchrony may be noted. The global left ventricular function may be reduced.
Appropriate treatment includes therapy for the prevention and control of arrhythmias, optimization of cardiac function, and screening family members for the same disease features. A history of sudden arrest is a major risk factor of future sudden death. Fainting spells, evidence of ventricular tachycardia, slowed conduction in the right ventricle, and marked enlargement of the right ventricle or left ventricular involvement are also major risks for sudden cardiac death. Athletes are often symptomatic and present because they push themselves beyond ordinary endurance during events. High levels of adrenaline, sudden changes in heart rate, increased ventricular stretching, and decreased awareness of pain all contribute to their particular vulnerability to sudden death.
Beta-blockers interfere with adrenaline and decrease heart rate. Because adrenaline may cause arrhythmias in ARVC, it is a common treatment drug (class II). Amiodarone is an antiarrhythmic and is effective against several rhythm disorders (class III). Sotalol, also an antiarrhythmic (class II/ III), is an option, but torsades de pointes is a side effect in some patients, so the drug's use must be monitored carefully. 6 An implantable cardioverterdefibrillator (ICD) may be necessary when there is an increased risk of sudden death. 3 
Conclusion
Arrhythmogenic right ventricular cardiomyopathy is an inherited heart muscle disease, characterized by progressive fibrofatty replacement of ventricular muscle. Echocardiography can be used to identify the abnormalities associated with ARVC. Patients may still be asymptomatic and their physicians may be unaware of their disease. ARVC risks include heart failure and sudden death. Sonographer awareness and careful scanning technique are essential in identifying this disease correctly. Patients with ARVC show thinning of the right ventricle wall, dilation of the RV chamber, or aneurysms in the RV wall. The disease may spread into the left ventricle. Serial evaluation of patients with suspected ARVC is recommended as clinical features may develop during the follow-up time.
